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ISSUES IN USING CONJOINT ANALYSIS TO 
VALUE HEALTH CARE WITHIN
CLINICAL STUDIES
Girod I, Marquis P
Mapi Values, Lyon, France
INTRODUCTION AND OBJECTIVES: Recent applica-
tions of conjoint analysis (CA) in health care showed the
technique’s potential for measuring benefits beyond tra-
ditional health outcomes, particularly patient preferences
(PP). However, further methodological work is needed to
generalize its application into clinical research. This ab-
stract discusses the issues addressed during a recent PP
research in benign prostatic hyperplasia (BPH) patients.
METHODS: Issues were addressed at the different stages
of PP design: 1) identify attributes to include in the sce-
narios; 2) choose attribute levels; 3) select scenarios to
present; 4) decide which was the suitable method to elicit
patient preferences; and 5) choose the CA. RESULTS: 1-
Attributes were identified using patient interviews, litera-
ture review and drug profiles (side-effect, daily cost, time
to onset). The selection of the most important attributes
for patients addressed the question of defining their rele-
vance. Six attributes were selected in our study. 2- At-
tribute levels were determined to make trade-off possible
while remaining realistic. The margin between these two
concepts was narrow for the attributes chosen, for exam-
ple the daily cost of medical treatment ranged from $1 to
$1.5. 3- A fractional factorial design was employed to de-
termine the 16 scenarios that were administered to keep
the patient burden acceptable (less than 12 minutes). Three
sets of scenarios in different orders were administered, as
order may affect the results of CA. 4- The method for PP
elicitation was discussed in order to find a common de-
sign to assess quality of life, PP and clinical criteria
within the same study. Auto-administration methods were
preferred to interview-administration, to limit clinician
burden and because of the sample size: 871 patients. Rat-
ing methods were chosen as the simplest approach. 5-
Data were analyzed using ordered probit regression tech-
niques. CONCLUSION: When following theoretical and
methodological guidelines for assessing PP, researchers
need to take into account study design, the size of the
sample and the number of outcomes measured within the
same study.
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ECONOMIC ASSESSMENT OF THE DIRECT 
SPECIFIC COST OF BENIGN PROSTATIC 
HYPERPLASIA IN FRANCE, HEALTH 
INSURANCE PERSPECTIVE
Chopin D1, Smadja C2, Taïeb C2
1Unit of Urology, University Hospital Centre, Creteil, France; 
2Pharmaco-Economic programs, Pierre Fabre Laboratories, 
Boulogne, France
OBJECTIVE: To investigate the monthly direct cost of
benign prostatic hyperplasia(BHP) from the health insur-
ance perspective and according to the management op-
tion: watchful waiting or medication. METHOD: 1.756
subjects with a non-complicated BHP diagnosed for over
3 months and without surgery antecedent have been in-
cluded between May and October 1999 by 316 general
practitioners. Two patient groups have been identified:
with medication (n  1561) or watchful waiting (n 
191). For each patient, the disease history and all specific
medical resources consumed during the last three months
have been collected: hospitalization, drugs, consultations
and lab tests. Clinical profile: Mean age: 67.7 years, Weight/
Length: 77.7 kg/171.6 cm, PAS/PAD: 138.4/79.1 mmHg,
BHP diagnostic: 3.5 years (/ 3.47), Score Interna-
tional-Prostate Symptom Score (I-PSS): 0 to 7 (mean
4.63): 28 %, 8 to 19(mean 12.82): 58%, 20 to 35(mean
23.87): 12% RESULTS: The total average specific direct
cost of care per month, calculated on all included pa-
tients was 26.2€ per patient: drug (39%), lab test (25%),
hospitalization (21%), consultations (15%). The break-
down of costs by severity shows that the disease progres-
sion induces higher cost: score I-PSS 0 to 7: 18.5€, score
I-PSS 8 to 19: 26.2€; score I-PSS 20 to 35: 47.3€. The eco-
nomic assessment shows a difference in favour of the
group with medication. (26€ versus 31.7€ per month).
CONCLUSION: The patients treated by BPH drug con-
stitute a lower financial burden for the Health Insurance
than patients without BPH drug. This difference, extrap-
olated to 68€ per year, is explained by the low reimburse-
ment rate (35%) of the BHP drug by the French Health
Insurance, and a best reimbursement rate of all other
resources used (hospitalization: 100%, consultations: 70%).
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THE IMPACT OF DEMENTIA ON THE QUALITY 
OF LIFE OF CAREGIVERS OF ELDERLY PEOPLE
Scuvée-Moreau J, Kurz X, Dresse A
Laboratory of Pharmacology, University of Liège, Liège, Belgium
OBJECTIVE: to assess the impact of dementia and its se-
verity on mental health, physical health and social func-
tioning of caregivers of elderly people living at home.
METHODS: Study population: 181 caregivers of subjects
aged 65 with mild (D1), moderate/mild (D2), moderate
(D3) or severe dementia (D4), 118 caregivers of non-de-
mented subjects aged 65 with (R2) or without (R1)
cognitive disorders. Generic quality of life (QOL) was as-
sessed with COOP/WONCA and SF-36 measures. De-
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pression was assessed using Beck Depression Inventory
(BDI). Medications were registered. RESULTS: COOP/
WONCA charts showed marked impairment of social ac-
tivities for caregivers of D3 patients (mean score: 2.6 ver-
sus 1.8, 2.1, 1.9, 1.9 and 1.5 for caregivers of respectively
D1, D2, D4, R2 and R1 subjects). Small differences ap-
peared in the other functional aspects. SF-36 showed
comparable mean Physical Component Scores (PCS) for
all caregivers, ranging from 43.5 to 46 according to co-
hort. Caregivers of D3 and/or D4 patients tended to have
lower scores in scales assessing Role limitations due to
Physical problems, Bodily Pain and General Health.
Mean Mental Component Scores (MCS) had the lower
values for caregivers of D3 (42.0) and D2 (44.7) patients
and the highest value for caregivers of R1 subjects (50.9).
Caregivers of D3 patients had the lowest scores in scales
used to score the MCS, namely Social Functioning, Emo-
tional role, Mental Health and Vitality. More than 60%
of caregivers of D3 patients suffered from depression ver-
sus 30% of caregivers of R1, R2 or D1 subjects and 43%
of caregivers of D2 or D4 patients. Results on correlation
with medications and association with cohabitation sta-
tus, age and gender will be presented. CONCLUSION:
moderate/mild to severe dementia has an impact on men-
tal health, physical health and social activities of caregiv-
ers. The impact appears particularly important for care-
givers of moderately demented patients (MMSE 10–14).
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EVALUATION OF THE CES-D IN SIX COUNTRIES 
USING RASCH ITEM RESPONSE THEORY
(IRT) ANALYSIS
Bushnell DM1, Whalley D2
1Health Research Associates, Inc., Seattle, WA, USA; 2Galen 
Research, Manchester, UK
OBJECTIVE: To evaluate the scaling properties of the
Centers for Epidemiologic Studies-Depression Scale (CES-D)
in Israel, Spain, Australia, Brazil, the United States, and
the Russian Federation through the application of the
one-parameter (Rasch) IRT model. METHODS: The
Longitudinal Investigation of Depression Outcomes (LIDO)
is an ongoing observational study in these six countries.
CES-D data (representing symptom-based severity of de-
pression) were gathered from a sample of patients exhib-
iting depressive symptoms, but not necessarily diagnosed
with major depression. Analyses were conducted to as-
sess unidimensionality through goodness-of-fit mean-
square (MNSQ) statistics. The hierarchical structure of
the scale was also examined through the spacing of cate-
gory threshold logit calibrations. RESULTS: Similar pat-
terns were noted across the six countries as shown by the
goodness-of-fit statistics. Three items with MNSQ values
below the recommended range (0.85 indicating redun-
dancy) were identical at each site (I felt depressed, I felt
sad, and I could not shake off the blues). Furthermore,
items that were above the range (1.25 indicating that
they yield responses that do not conform to the response
patterning of most other items) included two of the posi-
tively framed items: I felt that I was just as good as other
people and I felt hopeful about the future. All items cov-
ered the construct well for most language versions, al-
though some gaps in measurement were observed.
Finally, some degree of item overlap/redundancy was
evident in all language versions, with several items
sharing the same location on the underlying construct.
CONCLUSION: Although the CES-D is a commonly
employed measure of depression severity, it may be nec-
essary to take a closer look at its scalability. Such infor-
mation is vital for the appropriate use and interpretation
of multi-center and multi-national data resulting from
this instrument.
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GLOBAL INDEX OF SAFETY (GIS): A NEW 
INSTRUMENT TO ASSESS DRUG SAFETY: 
APPLICATION TO A PROSPECTIVE 
PHARMACOEPIDEMIOLOGICAL STUDY (EFESO)
Sacristán JA1, Gómez JC1, Badia X2, Kind P3, Gavart S4 and 
the EFESO Study Group
1Clinical Research Department, Lilly S.A., Madrid, Spain; 2Public 
Health Institute of Catalonia, Barcelona, Spain; 3Center for 
Health Economics, University of York, York, UK; 4Eli Lilly & 
Company, Windlesham, UK
OBJECTIVE: Develop a weighted, global index of safety
(GIS) and compare the safety profiles of olanzapine-treated
patients and patients treated with other antipsychotics
using data from an observational prospective pharma-
coepidemiological study (EFESO). METHODS: A total
of 194 psychiatrists rated through a survey the severity
(from 1 insignificant, to 5 extremely severe) of the most
common adverse events (AE) that occur with antipsycho-
tic treatment. The severity scores were then applied to the
AE occurring in the 2,949 EFESO patients resulting in
per-patient scores. A GIS was calculated for every group
of patients receiving the same treatment by averaging the
per-patient scores. The GIS was compared between the
olanzapine-treated patients and a control group (com-
posed of patients treated with all other antipsychotics) as
well as with patients treated specifically with risperidone
and haloperidol. RESULTS: The GIS calculated from the
control group (4.3) was 72% higher (worse score) than
that calculated for the olanzapine-treated patients (2.5)
(P  .001). The GIS for the risperidone- (3.6) and halo-
peridol- (6.0) treated patients were 44% and 140%
higher than that calculated for the olanzapine-treated pa-
tients (P  .001). CONCLUSIONS: The GIS is a new in-
strument that produces a single, weighted score facilitat-
ing the safety comparison of antipsychotic treatments in
terms of both AE frequency and severity. Application of
the GIS in the EFESO study showed that olanzapine-treated
patients had a significant better (lower) safety index com-
pared to the patients in the control group and compared
specifically to risperidone- and haloperidol-treated pa-
tients.
